Pyxis Oncology Inc To Discuss Preliminary Data From The Phase 1 Dose Escalation Trial Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Swayampakula Ramakanth - H.C. Wainwright & Co - Analyst : Good evening. This is from HCM. Right.

Question: Swayampakula Ramakanth - H.C. Wainwright & Co - Analyst : Sure. Certainly very interesting data in head and neck and obviously promising, considering the late stage patient status here. A couple of questions. One, the non-responders, what was the treatment status of the treatment experience status of these patients prior to coming into this trial? And also are their additional patients within that dose range, yet to be evaluated, especially among the head and neck cancer patients?

Question: Swayampakula Ramakanth - H.C. Wainwright & Co - Analyst : Interesting. Couple more questions, one on the next set of trials that you're planning to do. You had one trial set up for first line/ second line. How easy is it to get patients into such early lines of therapy? Especially when there are drugs out there?

Question: Swayampakula Ramakanth - H.C. Wainwright & Co - Analyst : Last question, Dr. Tolcher was almost answering my question, when you started talking about, their potentially other tumors that you would like to look at. So can you tell us a little bit more on that thought? Especially with the data that we have right now?

Question: Sam Slutsky - LifeSci Capital - Analyst : Hey, thanks for taking the question. Everyone. May have missed this but just for the HNSCC cohorts you're taking forward. Are you testing three different doses in that? And then how many patients are you looking to enroll across the combo study and then the two monotherapy arms?